ADC Therapeutics SA expected to post a loss of 50 cents a share - Earnings Preview

ADC Therapeutics SA

23/02/2024 06:12

* ADC Therapeutics SA  ADCT.N   ADCT.K  is expected to show
a fall
in quarterly revenue when it reports  results on February 26
(estimated) for the period ending December 31 2023
    * The Epalinges Vaud-based  company is expected to report a
78.0% decrease in revenue to $15.326 million from $69.8 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for ADC Therapeutics SA is
for a
loss of 50 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ADC
Therapeutics
SA is $7.50​, above​ its last closing price of $4.89. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.65       -0.63      -0.58     Beat    8.5
 Jun. 30 2023  -0.35       -0.46      -0.58     Missed  -26.9
 Mar. 31 2023  -0.76       -0.67      -0.74     Missed  -10.4​
 Dec. 31 2022  -0.21       -0.29      -0.30     Missed  -4.6
 ​​Sep.        -0.30       -0.35      -0.65     Missed  -84.2
 30 2022                                                
 Jun. 30 2022  -0.92       -0.91      -0.84     Beat    8.1​
 Mar. 31 2022  -0.69       -0.70      -0.22     Beat    68.4
 Dec. 31 2021  -0.86       -0.86      -0.45     Beat    47.5
 This summary was machine generated February 23 at 06:12 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)